术前骨肌减少症可预测EVAR术后远期死亡与心血管事件
该多中心研究纳入240例腹主动脉瘤腔内修复(EVAR)患者,用术前CT评估肌少症与骨量减少,中位随访5.0年。结果显示骨肌减少症组5年生存率55.8%,显着低于正常组89.4%,且为全因死亡与MACE的独立预测因素(HR 3.09、5.01)。
要点
- 术前骨肌减少症是EVAR术后远期全因死亡与MACE的独立预测因素。
- 单纯肌少症或单纯骨量减少未显示独立预后意义。
- 骨肌减少症可经常规CT机会性筛查识别,应纳入术前风险评估。
核心结论
- 术前骨肌减少症是EVAR术后远期死亡和主要不良心血管事件(MACE)的强独立预测因素,可经常规CT筛查识别。
研究设计与样本
- 多中心研究,纳入240例接受EVAR的患者,平均年龄77.8±7岁。
- 术前CT评估肌少症(L3骨骼肌指数)与骨量减少(L1椎体平均CT衰减值),骨肌减少症定义为两者并存。
- 采用多变量Cox比例风险回归分析全因死亡与MACE的独立预测因素,并校正临床相关预后因素。
- 中位随访5.0(2.8,6.8)年,期间65例死亡。
主要发现
- 分组:正常78例(32.5%)、单纯肌少症69例(28.8%)、单纯骨量减少32例(13.3%)、骨肌减少症61例(25.4%)。
- 骨肌减少症组预后最差,5年生存率55.8%,正常组为89.4%(P < .001)。
- 骨肌减少症是全因死亡的独立预测因素(HR 3.09;95%CI 1.44-6.65;P = .004)。
- 骨肌减少症是MACE的独立预测因素(HR 5.01;95%CI 1.58-15.91;P = .006)。
- 单纯肌少症或单纯骨量减少未显示独立预后意义;各组30天死亡率无显着差异。
关键数值与推荐
- 骨肌减少症定义:L3骨骼肌指数判定的肌少症与L1椎体平均CT衰减值判定的骨量减少同时存在。
- 5年生存率:骨肌减少症组55.8%,正常组89.4%(P < .001)。
- 全因死亡HR 3.09(95%CI 1.44-6.65;P = .004),MACE HR 5.01(95%CI 1.58-15.91;P = .006)。
临床怎么用
- 将术前CT机会性筛查骨肌减少症纳入EVAR术前风险评估,识别高危患者。
- 对骨肌减少症患者优化心血管管理并加强术后随访监测。
- 单纯肌少症或骨量减少者预后意义有限,风险分层应关注两者并存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Osteosarcopenia, the coexistence of sarcopenia and osteopenia, has recently emerged as a novel pathological concept. This study aimed to investigate the clinical significance of preoperative osteosarcopenia as a predictor of long-term outcomes in patients undergoing endovascular aneurysm repair (EVAR). METHODS: A total of 240 patients (mean age, 77.8 ± 7 years) were included. Sarcopenia and osteopenia were assessed using opportunistic preoperative computed tomography (CT) scans. Sarcopenia was defined by the skeletal muscle index at the L3 level, and osteopenia was defined by the mean CT attenuation of the L1 vertebral body. Osteosarcopenia was defined as the concurrent presence of both conditions. To identify independent predictors of all-cause mortality and major adverse cardiovascular events (MACEs), multivariable Cox proportional hazards regression models were employed, adjusting for clinically relevant prognostic factors. RESULTS: Patients were categorized into 4 groups: normal (n = 78, 32.5%), sarcopenia alone (n = 69, 28.8%), osteopenia alone (n = 32, 13.3%), and osteosarcopenia (n = 61, 25.4%). During a median follow-up of 5.0 (2.8, 6.8) years, 65 patients died. The osteosarcopenia group exhibited the poorest prognosis, with a 5-year survival rate of 55.8% compared with 89.4% in the normal group (P < .001). Multivariable analysis identified osteosarcopenia as a potent independent predictor of all-cause mortality (hazard ratio [HR], 3.09; 95% confidence interval [CI], 1.44-6.65; P = .004) and MACE (HR, 5.01; 95% CI, 1.58-15.91; P = .006). In contrast, sarcopenia or osteopenia alone did not show independent prognostic significance. No significant differences were observed in 30-day mortality among the groups. CONCLUSIONS: Preoperative osteosarcopenia is a powerful, independent predictor of long-term mortality and MACE following EVAR. Since this condition can be readily identified through routine CT screening, it should be integrated into surgical risk assessment to optimize patient selection and facilitate personalized perioperative care.Clinical ImpactThis multicenter study demonstrates that preoperative osteosarcopenia-the concurrent loss of muscle and bone-is a potent independent predictor of mortality and major adverse cardiovascular events after endovascular aneurysm repair, whereas neither condition alone holds prognostic significance. This finding is innovative as it identifies a synergistic frailty phenotype previously overlooked by single-tissue assessments. For clinicians, these results advocate for the integration of opportunistic CT screening into routine preoperative workflows. By utilizing existing imaging to identify osteosarcopenia, practitioners can refine risk stratification, optimize cardiovascular management, and implement intensified postoperative surveillance for this high-risk patient group.
引用
- Sugiura H, Shibata T, Iba Y, et al. Preoperative Osteosarcopenia Predicts Long-term Mortality and Cardiovascular Events After Endovascular Aneurysm Repair. J Endovasc Ther. 2026. PMID: 42515986. doi:10.1177/15266028261468920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。